Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Texas ephedrine proposal

This article was originally published in The Tan Sheet

Executive Summary

State Board of Health Regulatory Committee tables discussion of the proposal to require the FDA MedWatch toll-free number on all ephedrine-containing dietary supplements until its January meeting. The committee plans to hold a stakeholder meeting to discuss alternate language in December. The proposed rule was scheduled to be presented to the committee Nov. 18 (1"The Tan Sheet" Nov. 15, p. 3). House Government Reform Committee Chair Dan Burton (R-Ind.) voices "grave concerns" with the MedWatch system in a Nov. 16 letter to the Texas Department of Health. "I continue to be concerned that the FDA has not developed an effective system to monitor the adverse events of dietary supplements," Burton says. "One of my concerns is that the development of this proposal will send Texans in to a reporting system that will not be responsive to their needs." Burton also asks if the requirement would be extended to OTCs, Rx drugs and special nutritional products including infant formula
Advertisement

Related Content

Ephedrine Labeling MedWatch Reference Proposed In Texas
Ephedrine Labeling MedWatch Reference Proposed In Texas

Topics

Advertisement
UsernamePublicRestriction

Register

PS090597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel